Loading...
XNASXENE
Market cap2.91bUSD
Dec 23, Last price  
38.14USD
1D
-1.27%
1Q
-2.03%
Jan 2017
395.32%
IPO
218.63%
Name

Xenon Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:XENE chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
28.05%
Rev. gr., 5y
97.87%
Revenues
0k
-100.00%
6,918,00014,308,00027,356,00028,370,00015,577,0001,803,000311,00006,829,00032,166,00018,437,0009,434,0000
Net income
-182m
L+45.48%
-11,992,000-4,301,00012,032,00013,018,000-15,752,000-22,997,000-30,704,000-34,497,000-41,595,000-28,837,000-78,882,000-125,373,000-182,393,000
CFO
-145m
L+47.65%
-13,689,00045,573,000-3,322,000266,000-18,103,000-19,567,000-28,726,000-34,724,000-4,632,000-48,124,000-69,502,000-98,430,000-145,327,000
Earnings
Feb 26, 2025

Profile

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
URL
https://www.xenon-pharma.com/
IPO date
Oct 17, 2014
Employees
203
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
9,434
-48.83%
18,437
-42.68%
Cost of revenue
381,566
244,344
172,893
Unusual Expense (Income)
NOPBT
(381,566)
(234,910)
(154,456)
NOPBT Margin
Operating Taxes
292
118
(6)
Tax Rate
NOPAT
(381,858)
(235,028)
(154,450)
Net income
(182,393)
45.48%
(125,373)
58.94%
(78,882)
173.54%
Dividends
Dividend yield
Proceeds from repurchase of equity
353,487
278,471
447,283
BB yield
-11.47%
-11.67%
-32.82%
Debt
Debt current
1,299
488
605
Long-term debt
20,507
20,382
15,909
Deferred revenue
Other long-term liabilities
(509)
Net debt
(909,068)
(699,899)
(535,260)
Cash flow
Cash from operating activities
(145,327)
(98,430)
(69,502)
CAPEX
(5,617)
(2,894)
(2,050)
Cash from investing activities
(117,170)
(296,003)
(246,770)
Cash from financing activities
353,522
278,471
447,543
FCF
(383,798)
(239,412)
(160,092)
Balance
Cash
638,082
592,087
551,774
Long term investments
292,792
128,682
Excess cash
930,874
720,297
550,852
Stockholders' equity
771,157
579,389
432,538
Invested Capital
167,667
152,034
125,752
ROIC
ROCE
EV
Common stock shares outstanding
66,889
60,542
43,627
Price
46.06
16.81%
39.43
26.22%
31.24
103.12%
Market cap
3,080,908
29.06%
2,387,177
75.15%
1,362,922
156.55%
EV
2,171,840
1,687,278
835,394
EBITDA
(378,025)
(233,286)
(153,550)
EV/EBITDA
Interest
5,512
Interest/NOPBT